Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Australia / NCT06194461
Starting soon Observational

LTFU for All Cell and Gene Therapy Studies

NCT06194461 · tracked via the Priya Life Science Australia tracker
Sponsor
AstraZeneca
Phase
Observational
Started
2025-09-17
Last updated
2025-06-27

Condition(s) studied

Hepatocellular CarcinomaProstate Cancer

Investigational drug(s) / intervention(s)

AZD5851 →AZD0754 →

AZD5851: Safety follow-up for up to 15 years of subjects who received AZD5851 in study NCT06084884.

AZD0754: Safety follow-up for up to 15 years of subjects who received AZD0754 in study NCT06267729.

Study summary

Master LTFU study will monitor the long-term safety and tolerability of cell or gene therapy study participants from AstraZeneca for up to 15 years post last cell or gene therapy treatment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
130 Years
Healthy volunteers
No
Inclusion Criteria: 1. The participant has received a cell or gene therapy in another AstraZeneca protocol. 2. Provision of signed and dated, written informed consent before any study-specific procedures. Exclusion Criteria: Not applicable \-

Primary outcome measure(s)

  • Incidence of specific AEs — Maximum of 15 years post dosing
    To determine long-term safety of previous treatment with applicable cell and gene therapy products

Trial sites (25)

FacilityCityRegionStatus
Research Site Phoenix Arizona
Research Site Duarte California
Research Site Orange California
Research Site San Francisco California
Research Site Washington D.C. District of Columbia
Research Site Jacksonville Florida
Research Site Tampa Florida
Research Site Atlanta Georgia
Research Site Westwood Kansas
Research Site Rochester Minnesota
Research Site St Louis Missouri
Research Site Hackensack New Jersey
Research Site New York New York
Research Site Columbus Ohio
Research Site Portland Oregon
Research Site Philadelphia Pennsylvania
Research Site Pittsburgh Pennsylvania
Research Site Houston Texas
Research Site East Melbourne Australia
Research Site Kashiwa Japan
Research Site Kyoto Japan
Research Site Osakasayama-shi Japan
Research Site Seoul South Korea
Research Site Seoul South Korea
Research Site Seoul South Korea

More AstraZeneca trials in Australia

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer Active, not recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF. Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight Recruiting

Other trials for the same condition

PSMA PET Combined With MRI for the Detection of PCa Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation Recruiting
Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer Active, not recruiting
Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study). Recruiting
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06194461 on ClinicalTrials.gov ↗ ← All trials in Australia